Mackenzie Financial Corp Grows Stock Holdings in Insulet Co. (NASDAQ:PODD)

Mackenzie Financial Corp boosted its holdings in shares of Insulet Co. (NASDAQ:PODD) by 25.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,029 shares of the medical instruments supplier’s stock after buying an additional 1,428 shares during the quarter. Mackenzie Financial Corp’s holdings in Insulet were worth $1,525,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd boosted its position in shares of Insulet by 227.3% in the third quarter. Qube Research & Technologies Ltd now owns 386,687 shares of the medical instruments supplier’s stock worth $61,673,000 after purchasing an additional 268,553 shares during the period. Assenagon Asset Management S.A. raised its position in Insulet by 119.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 79,375 shares of the medical instruments supplier’s stock worth $17,223,000 after purchasing an additional 43,147 shares during the period. Asset Management One Co. Ltd. increased its position in shares of Insulet by 33.7% during the fourth quarter. Asset Management One Co. Ltd. now owns 36,677 shares of the medical instruments supplier’s stock worth $8,048,000 after acquiring an additional 9,240 shares during the period. Graham Capital Management L.P. boosted its stake in shares of Insulet by 689.8% during the third quarter. Graham Capital Management L.P. now owns 23,095 shares of the medical instruments supplier’s stock valued at $3,683,000 after purchasing an additional 20,171 shares in the last quarter. Finally, Aquila Investment Management LLC bought a new position in shares of Insulet during the fourth quarter valued at approximately $1,302,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on PODD shares. Barclays dropped their price objective on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research note on Monday, February 26th. Stifel Nicolaus raised their target price on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a report on Monday, February 5th. Piper Sandler reduced their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $243.21.

Insider Buying and Selling at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.80% of the stock is currently owned by company insiders.

Insulet Stock Performance

PODD opened at $167.27 on Wednesday. The firm has a market capitalization of $11.71 billion, a PE ratio of 57.48, a PEG ratio of 2.96 and a beta of 0.98. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $335.91. The firm’s 50-day moving average price is $172.96 and its 200 day moving average price is $179.44. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.73. The firm had revenue of $509.80 million for the quarter, compared to analyst estimates of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. Insulet’s quarterly revenue was up 37.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.55 earnings per share. As a group, sell-side analysts expect that Insulet Co. will post 3.08 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.